Interim Guidance for Health Care Providers regarding the Management
Approach of Patients with Suspected E-cigarette, or Vaping, Product
Use-Associated Lung Injury (EVALI)
Date: Thursday, November 21, 2019
Time: 2:00pm-3:00pm (Eastern Time)
U.S. Food and Drug Administration (FDA), state and local health
departments, and public health and clinical stakeholders continue to
investigate a national outbreak of electronic cigarette (e-cigarette), or
vaping, product use–associated lung injury (EVALI).
EVALI remains a diagnosis of exclusion because, at present, no specific
test or marker exists for its diagnosis, and evaluation should be guided
by clinical judgment. Because patients with EVALI can present with
symptoms similar to influenza or other respiratory infections (e.g.,
fever, cough, headache, myalgias, or fatigue), it might be difficult to
differentiate EVALI from influenza or CAP (community-acquired pneumonia)
on initial presentation, and EVALI may cooccur with respiratory infections.
A large number of patients will be presenting to healthcare facilities
with respiratory symptoms during the winter season who may not meet
criteria for hospital admission, and this will be happening in the
context of a national outbreak of EVALI.
During this COCA Call, US health care providers will learn
recommendations for managing patients with suspected or known EVALI when
respiratory infections such as influenza are more prevalent in the
community, as published in MMWR on
November 19, 2019.
are unable to attend this live COCA Call, it
will be available on-demand a few days after the call.